Asensus Surgical — TransEnterix — IPO Roadshow (April 2014)
30 slides from Asensus Surgical's IPO roadshow presentation, Apr 2, 2014
Slide 1: Todd M. Pope, President & CEO; Joe Slattery, EVP & CFO
Todd M. Pope, President & CE O Joe Slattery, EVP & CFO April 2, 2014 Exhibit 99.1
Slide 2: Cautionary Statement
2 Cautionary Statement Any statements contained in this presentation that do not describe historical facts, including statements about the beliefs and expectations of TransEnterix, Inc. (“TransEnterix,” "we" or "our"), may constitute forward-looking statements as that term is defined by the United S
Slide 3: Advancing Surgery Through Innovation
Advancing Surgery Through Innovation
Slide 4: Transaction Overview
4 Transaction Overview Issuer: TransEnterix, Inc. Ticker (Exchange): TRXC (NYSE MKT) (1) Amount Offered: $50 million Over-Allotment Option: 15% Lock-up Provision: 90 days Expected Pricing: April 10, 2014 Bookrunners: Stifel / RBC Capital Markets Use of Proceeds: For research and development, sales a
Slide 5: Investment Highlights
Investment Highlights 5 The SurgiBot System is currently under development Technology Focus Solution Market Experience • Surgical robotics • Developing patient-side robotic platform: SurgiBot • Addresses unmet needs in today’s robotic offerings • Cost effective • Broad procedure applicability • Larg
Slide 6: Company History
6 2006 2009 2010 2012 2013 Company History • TransEnterix founded • FDA 510(K) clearance for Spider Surgical System • CE Mark clearance and release of Spider Surgical System • >3,500 SPIDER cumulative procedures performed to date • Began SurgiBot development • SurgiBot preclinical labs
Slide 7: Surgical Progress = Less Invasive
7 Surgical Progress = Less Invasive Open Surgery Rigid Laparoscopy (1989) Flexible Laparoscopy (2010)
Slide 8: Spider Surgical System Enabling Flexible Laparoscopy
8 Spider Surgical System Enabling Flexible Laparoscopy • Internal (intra-abdominal) triangulation • Flexible, articulating instruments for dissection and retraction • True left/right instrumentation • Lower profile port of access • Over 3,500 procedures performed • Broad procedural mix
Slide 9: SurgiBot
SurgiBot Powered and Robotically-enabled Next-generation Platform* *The SurgiBot System is currently under development TM
Slide 10: Benefits of Surgical Robotics
10 Benefits of Surgical Robotics Improved dissection and retraction strength Enhanced precision and control Improved surgeon ergonomics Advanced visualization Benefits of Surgical Robotics
Slide 11: Worldwide daVinci Procedures
11 Worldwide daVinci Procedures Source: ISRG Investor Presentation, 2/21/2014
Slide 12: Multi-Port SurgiBot Purpose Built for Abdominal Surgery
12 The SurgiBot System is currently under development Multi-Port SurgiBot Purpose Built for Abdominal Surgery (2) ISRG investor call, 1/23/2014 (1) (1) Surgeon scrubbed-in Multi-quadrant utility Reduced incisions Internal triangulation Articulating instruments Space for assistant Cost ~$1.5M (2) ~$5
Slide 13: SurgiBot First Patient-side Robotic Platform
13 The SurgiBot System is currently under development Surgeon scrubbed-in Easily repositioned for multi- quadrant surgery Flexible, articulating channels & instruments Steerable 3DHD Small, mobile platform Cost effective platform SurgiBot First Patient-side Robotic Platform
Slide 14: SurgiBot First Patient-side Robotic Platform
14 The SurgiBot System is currently under development SurgiBot First Patient-side Robotic Platform 3DHD Optics/Cart SurgiBot
Slide 15: SurgiBot Prototype Video
15 The SurgiBot System is currently under development [Video of SurgiBot System Prototype] SurgiBot First Patient-side Robotic Platform
Slide 16: Procedure Market Opportunity
16 Procedure Market Opportunity Bariatric Surgery Cholecystectomy Colorectal Gynecology/Urology Targeted US Procedures 160K 1,140K 363K 230K ~2M US Laparoscopic Procedures Source: Millennium Research Group US Markets Laparoscopic Devices 2014
Slide 17: Large Addressable Market
Large Addressable Market 17 1,566 2,054 930 458 Source: CDC Over 5,000 Hospitals in the United States # of Beds Under 50 50-200 - Over 400
Slide 18: Hospital Market Opportunity
18 Hospitals without Robotic Capability Hospitals with Robotic Capability Hospital Market Opportunity • Invested in the strategic and competitive value of robotic surgery • ROI expectations changing/under pressure • Potential for diversification of robotic solutions • Procedures • Price • Facilities
Slide 19: Significant Base of Underserved Hospitals
Significant Base of Underserved Hospitals 19 Mid/Small Hospitals Surgery Centers • >3,000 w/ <300 beds • >80% lack robotic offering • Losing market share to robotic facilities • Represent >800K target annual procedures • ~5,000 in US • Economics driving rapid procedure growth • SurgiBot will offer v
Slide 20: Combining Advanced Technology AND Maximizing Value
20 Combining Advanced Technology AND Maximizing Value Price Traditional Laparoscopy >$10B Revenue Low Growth Surgical Robotics >$2B Revenue High Growth
Slide 21: Highlights – Instrumentation
21 Highlights – Instrumentation Instrumentation Needs By Procedure Status The SurgiBot System is currently under development Chole Bariatrics GYN SPIDER SurgiBot Grasper Launched Developed Dissector Launched Developed Hook Launched Developed Clip Applier Launched Developed Shears Launched Developed
Slide 22: Operating Capabilities & Talent
Operating Capabilities & Talent 22 Rapid Prototyping R&D Team Broad Experience cGMP Manufacturing
Slide 23: Management Team
Management Team 23 Prior Experience Todd M. Pope President and Chief Executive Officer Joe Slattery EVP and Chief Financial Officer Richard Mueller Chief Operating Officer Mohan Nathan Vice President of Global Marketing Tammy Carrea Vice President, Quality and Regulatory Affairs Nicole Bell Vice Pre
Slide 24: Board of Directors and Healthcare Investors
24 Board of Directors and Healthcare Investors Board of Directors Healthcare Investors • Phillip Frost, M.D. – CEO and Chairman of OPKO Health – Chairman of Teva Pharmaceuticals • Jane Hsiao, Ph.D., MBA – Former Chairman of SafeStitch – Vice Chairman and CTO of OPKO Health • Aftab Kherani, M.D. – Pr
Slide 25: Regulatory Strategy
Regulatory Strategy 25 2013 2014 2015 • 510(k) pathway • General intended use for laparoscopic abdominal access • Design & Pre-clinical Testing • Pre-submission FDA Meeting • Regulatory Clearances • Global Launch • First Human Procedures • Regulatory Submissions
Slide 26: Financial Information
Financial Information
Slide 27: Recurring Revenue Model
Recurring Revenue Model 27 Instruments and Accessories Service Capital Equipment The SurgiBot System is currently under development US Pricing: • Market-specific pricing • Distributors provide service/support International: • Capital sale ~$500K • Instruments ~$1,000-1,500/procedure • Service ~$50K/
Slide 28: Financial Highlights
Financial Highlights 28 The SurgiBot System is currently under development • Cash – Balance at 12/31/2013 $16.2M – Q4 ‘13 burn $8.7M, incl. $0.9M debt service and $0.7M capital equipment • Capital Sales Reps – Hire 5-8 early 2015 – ~15 by launch – ~30 to cover US – Supported by clinical and field se
Slide 29: 2014 Key Objectives
2014 Key Objectives 29 • FDA Pre-filing Submission - Q1 • Launch Flexible Advanced Energy Device - Q2 • Clinical SurgiBot Cases Begin - Q3 • SurgiBot FDA/CE Filings - Q4 Completed
Slide 30: Investment Highlights
Focus Technology Solution Market Experience Investment Highlights 30 The SurgiBot System is currently under development • Surgical robotics • Developing patient-side robotic platform: SurgiBot • Addresses unmet needs in today’s robotic offerings • Cost effective • Broad procedure applicability • Lar